These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24140031)

  • 1. No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.
    Franco S; Casadellà M; Noguera-Julian M; Clotet B; Tural C; Paredes R; Martinez MA
    J Clin Virol; 2013 Dec; 58(4):726-9. PubMed ID: 24140031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
    Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
    PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.
    Dryer PD; Limketkai BN; Martin CM; Ma G; Sherman KE; Taylor LE; Mayer KH; Jamieson DJ; Blackard JT
    J Antimicrob Chemother; 2009 Nov; 64(5):945-8. PubMed ID: 19767319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
    Treviño A; de Mendoza C; Parra P; Rodríguez C; Madejón A; Plaza Z; del Romero J; Poveda E; Soriano V
    Antivir Ther; 2011; 16(3):413-6. PubMed ID: 21555824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China].
    Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5.
    Legrand-Abravanel F; Henquell C; Le Guillou-Guillemette H; Balan V; Mirand A; Dubois M; Lunel-Fabiani F; Payan C; Izopet J
    Antivir Ther; 2009; 14(5):723-30. PubMed ID: 19704176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
    Hedskog C; Dvory-Sobol H; Gontcharova V; Martin R; Ouyang W; Han B; Gane EJ; Brainard D; Hyland RH; Miller MD; Mo H; Svarovskaia E
    J Viral Hepat; 2015 Nov; 22(11):871-81. PubMed ID: 25784085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
    Xu S; Doehle B; Rajyaguru S; Han B; Barauskas O; Feng J; Perry J; Dvory-Sobol H; Svarovskaia ES; Miller MD; Mo H
    Antivir Ther; 2017; 22(7):587-597. PubMed ID: 28248189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    Ngwaga T; Kong L; Lin D; Schoborg C; Taylor LE; Mayer KH; Klein RS; Celentano DD; Sobel JD; Jamieson DJ; King CC; Tavis JE; Blackard JT
    PLoS One; 2020; 15(8):e0237162. PubMed ID: 32750098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection.
    Maimone S; Tripodi G; Musolino C; Cacciola I; Pollicino T; Raimondo G
    Antivir Ther; 2015; 20(2):245-7. PubMed ID: 25171743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.
    Newsum AM; Molenkamp R; van der Meer JT; Rebers SP; Prins M; van der Valk M; Schinkel J
    J Hepatol; 2018 Oct; 69(4):968-970. PubMed ID: 30227918
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance.
    Götte M
    Curr Opin Virol; 2014 Oct; 8():104-8. PubMed ID: 25128987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
    Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
    Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients.
    Castilho MC; Martins AN; Horbach IS; Perez Rde M; Figueiredo FA; Pinto Pde T; Nabuco LC; Lima DB; Tanuri A; Porto LC; Ferreira Júnior Oda C
    Mem Inst Oswaldo Cruz; 2011 Dec; 106(8):968-75. PubMed ID: 22241118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.